Denali Therapeutics Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $3.6Mn |
Net Profits | $-127.55Mn |
Net Profit Margins | -3539.21% |
Denali Therapeutics Inc. Common Stock’s revenue jumped +Inf% since last year same period to $3.6Mn in the Q2 2026. On a quarterly growth basis, Denali Therapeutics Inc. Common Stock has generated +Inf% jump in its revenue since last 3-months.
Denali Therapeutics Inc. Common Stock’s net profit fell -2.77% since last year same period to $-127.55Mn in the Q2 2026. On a quarterly growth basis, Denali Therapeutics Inc. Common Stock has generated 0.7% jump in its net profits since last 3-months.
Denali Therapeutics Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -3539.21% in the Q2 2026. On a quarterly growth basis, Denali Therapeutics Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.67 |
EPS Estimate Current Year | -0.67 |
Denali Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.67 - a 6.94% jump from last quarter’s estimates.
Denali Therapeutics Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.67.
Key Ratios
Earning Per Share (EPS) | -0.68 |
Denali Therapeutics Inc. Common Stock’s earning per share (EPS) jumped 5.56% since last year same period to -0.68 in the Q2 2026. This indicates that the Denali Therapeutics Inc. Common Stock has generated 5.56% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-06 | -0.72 | -0.68 | 5.56% |
2026-05-07 | -0.71 | -0.69 | 2.82% |
